iCAD (NASDAQ:ICAD) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.
Shares of ICAD stock traded down $0.09 on Thursday, hitting $6.74. 139,680 shares of the stock were exchanged, compared to its average volume of 134,826. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.33 and a current ratio of 1.47. iCAD has a one year low of $2.42 and a one year high of $7.45. The firm has a 50 day moving average price of $6.42.
iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Thursday, August 1st. The technology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $7.33 million during the quarter, compared to the consensus estimate of $6.69 million. iCAD had a negative return on equity of 69.95% and a negative net margin of 43.88%. Equities analysts predict that iCAD will post -0.4 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. boosted its stake in iCAD by 96,087.0% in the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock worth $82,000 after purchasing an additional 22,100 shares during the period. Spark Investment Management LLC purchased a new stake in shares of iCAD in the 1st quarter valued at about $185,000. Deutsche Bank AG raised its holdings in shares of iCAD by 33.5% in the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after acquiring an additional 9,023 shares in the last quarter. Columbia Pacific Advisors LLC raised its holdings in shares of iCAD by 218.0% in the 1st quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock valued at $329,000 after acquiring an additional 43,600 shares in the last quarter. Finally, EAM Global Investors LLC purchased a new stake in shares of iCAD in the 1st quarter valued at about $984,000. Institutional investors and hedge funds own 18.98% of the company’s stock.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Featured Story: What is included in the gross domestic product?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.